Skip to main content

Advertisement

SpringerLink
Log in

Introduction of therapeutic reference pricing in Slovenia and its economic consequences

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Objectives

To evaluate the economic outcomes that arose from the introduction of therapeutic reference pricing (TRP) into Slovenian practice in 2013, based on the first three therapeutic classes, namely proton-pump inhibitors (PPIs), angiotensin-converting-enzyme inhibitors (ACEIs), and lipid-lowering agents (LLAs).

Methods

National health claims data on prescription medicines from January 2011 to December 2015 were analyzed. Monthly medicine expenditure, medicine consumption, changes in medicine use, and market competition (Herfindahl–Hirschman index) were determined to assess the TRP impact on market dynamics. Interrupted time series analysis was used to assess the TRP cost-saving potential.

Results

Medicine expenditure in all three therapeutic classes was decreasing prior to TRP; however, with the TRP introduction, the cost for ACEIs and LLAs fell 25 and 45%, respectively. The costs for PPIs decreased by 10%, but the cost reductions before TRP were greater. After TRP introduction, the downward trend for monthly medicine expenditure was less steep; coefficient changes from −20,798 to −363 for PPIs (p < 0.001), from −18,175 to −4862 for ACEIs (p = 0.001) and from −10,669 to −2761 for LLAs (p = 0.105) were observed. Consumption of any therapeutic class or their market competition were not changed significantly. An increased use of the reference pantoprazole (PPIs) was observed and the market position of ezetimibe was deteriorated significantly after TRP introduction. However, the demand for the references simvastatin (LLAs) and ramipril (ACEIs) did not increase.

Conclusions

The Slovenian TRP system was established as an effective cost-containment measure. However, pitfalls arising from a country-specific TRP should be considered when introducing this policy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. von der Schulenburg, F., Vandoros, S., Kanavos, P.: The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. Health Econ. Rev. 1(1), 18 (2011). doi:10.1186/2191-1991-1-18

    Article  PubMed  PubMed Central  Google Scholar 

  2. Galizzi, M.M., Ghislandi, S., Miraldo, M.: Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics 29(1), 17–33 (2011). doi:10.2165/11537860-000000000-00000

    Article  PubMed  Google Scholar 

  3. Ess, S.M., Schneeweiss, S., Szucs, T.D.: European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21(2), 89–103 (2003)

    Article  PubMed  Google Scholar 

  4. Usher, C., Barry, M.: A reference pricing system for Ireland. Expert Rev. Pharm. Out. Res. 12(6), 675–677 (2012). doi:10.1586/erp.12.66

    Google Scholar 

  5. Health Insurance Institute of Slovenia: Therapeutic reference pricing system in Slovenia—explanation for the insured population [in Slovenian]. http://www.zzzs.si/zzzs/internet/zzzs.nsf/o/6A6BD0CD7CB327B3C1257BD900451900?OpenDocument (2013). Accessed 5 June 2016

  6. Forum of International Research and Development Pharmaceutical Companies EIG: Health insurance institute of Slovenia has introduced the first therapeutic class of medicines [in Slovenian]. http://firdpc.com/sl/Aktualno/ZZZS_uvaja_prvo_terapevtsko_skupino_zdravil_dopolnjeno/ (2013). Accessed 26 Nov 2016

  7. Wallace, L.S.: A view of health care around the world. Ann. Fam. Med. 11(1), 84 (2013). doi:10.1370/afm.1484

    Article  PubMed  PubMed Central  Google Scholar 

  8. A World Health Organization: Essential medicines and health products information portal, experiences with reference pricing. http://apps.who.int/medicinedocs/en/d/Js4912e/3.3.html (2003). Accessed 20 Oct 2016

  9. Forum of International Research and Development Pharmaceutical Companies EIG: Opinion on therapeutic reference pricing [in Slovenian]. http://www.firdpc.com/sl/Sodelovanje_z_delezniki/ (2014). Accessed 26 Nov 2016

  10. Forum of International Research and Development Pharmaceutical Companies EIG: Therapeutic reference pricing is harmful to patients [in Slovenian]. http://www.firdpc.com/sl/Dogodki_in_novice/Terapevtske_skupine_zdravil/ (2013). Accessed 26 Nov 2016

  11. Kalo, Z., Abonyi-Toth, Z., Bartfai, Z., Voko, Z.: Pitfalls associated with the therapeutic reference pricing practice of asthma medication. BMC Pulm. Med. 12, 35 (2012). doi:10.1186/1471-2466-12-35

    Article  PubMed  PubMed Central  Google Scholar 

  12. Health Insurance Institute of Slovenia: [Introduction of the therapeutic reference pricing into Slovenian health care system—explanation for the insured population] Uvedba sistema najvišjih priznanih vrednosti za terapevtske skupine zdravil—pojasnilo za zavarovane osebe [In Slovenian]. http://www.zzzs.si/zzzs/internet/zzzs.nsf/o/6A6BD0CD7CB327B3C1257BD900451900?OpenDocument (2013). Accessed 4 Mar 2016

  13. Brekke, K.R., Konigbauer, I., Straume, O.R.: Reference pricing of pharmaceuticals. J. Health Econ. 26(3), 613–642 (2007). doi:10.1016/j.jhealeco.2006.11.003

    Article  PubMed  Google Scholar 

  14. Kalo, Z., Muszbek, N., Bodrogi, J., Bidlo, J.: Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 80(3), 402–412 (2007). doi:10.1016/j.healthpol.2006.04.002

    Article  PubMed  Google Scholar 

  15. Organisation for Economic Co-operation and Development (OECD): Pharmaceutical pricing policies in a global market. http://apps.who.int/medicinedocs/documents/s19834en/s19834en.pdf (2008). Accessed 20 Oct 2016

  16. Dylst, P., Vulto, A., Simoens, S.: The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev. Pharm. Out. Res. 11(6), 729–737 (2011). doi:10.1586/erp.11.70

    Google Scholar 

  17. Online Database of Medicinal Products in Slovenia. http://www.cbz.si/cbz/bazazdr2.nsf/Search/$searchForm?SearchView (2016). Accessed 10 Aug 2016

  18. Wagner, A.K., Soumerai, S.B., Zhang, F., Ross-Degnan, D.: Segmented regression analysis of interrupted time series studies in medication use research. J. Clin. Pharm. Ther. 27(4), 299–309 (2002)

    Article  CAS  PubMed  Google Scholar 

  19. Leopold, C., Zhang, F., Mantel-Teeuwisse, A.K., Vogler, S., Valkova, S., Ross-Degnan, D., Wagner, A.K.: Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses. Int. J. Equity Health 13, 53 (2014). doi:10.1186/1475-9276-13-53

    Article  PubMed  PubMed Central  Google Scholar 

  20. WHO Collaborating Centre for Drug Statistics Methodology: Definition and general considerations. http://www.whocc.no/ddd/definition_and_general_considera/ (2016). Accessed 9 Aug 2016

  21. Statistical Office of the Republic of Slovenia: Population number and structure. http://www.stat.si/StatWeb/en/home (2016). Accessed 9 Aug 2016

  22. Frakt, A.: The incidental economist. The health services research blog. Market concentration and entry. http://theincidentaleconomist.com/wordpress/market-concentration-and-entry/. Accessed 16 Aug 2016

  23. Investopedia: Herfindahl–Hirschman Index—HHI. http://www.investopedia.com/terms/h/hhi.asp#ixzz4H0ZEoISh (2016). Accessed 16 Aug 2016

  24. Bobocea, L., Spiridon, S., Petrescu, L., Gheorghe, C.M., Purcarea, V.L.: The management of external marketing communication instruments in health care services. J. Med. Life 9(2), 137–140 (2016)

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Health Insurance Institute of Slovenia: [Annual report of the Health Insurance Institute of Slovenia for 2014] Poslovno poročilo Zavoda za zdravstveno zavarovanje Slovenije za leto 2014 [In Slovenian]. http://www.zzzs.si/ZZZS/info/egradiva.nsf/o/9B52139ED62405F7C1257DFD00573AF8?OpenDocument (2015). Accessed 4 Feb 2016

  26. National Institute of Public Health: Medicine use in an ambulatory healthcare in 2014 [in Slovenian]. http://www.nijz.si/sites/www.nijz.si/files/datoteke/poraba_ambulantno_predpisanih_zdravil_v_sloveniji_2014.pdf (2015). Accessed 5 Mar 2017

  27. Brekke, K.R., Canta, C., Straume, O.R.: Reference pricing, generic entry, and pharmaceutical prices. http://www.hec.unil.ch/documents/seminars/iems/1717.pdf.pdf (2005). Accessed 8 Mar 2017

  28. Dylst, P., Vulto, A., Simoens, S.: Reference pricing systems in Europe: characteristics and consequences. Generics Biosimilar Initiat. J. 1(3–4), 127–131 (2012)

    Article  Google Scholar 

  29. Third Slovenian Meeting on Clinical Pharmacology: The safe use of medicines—introduction of therapeutic reference pricing. http://ktf.si/dogodki/3-slovensko-srecanje-o-klinicni-farmakologiji-varna-uporaba-zdravil/ (2015). Accessed 21 Oct 2016

  30. Dunne, S., Shannon, B., Dunne, C., Cullen, W.: Patient perceptions of generic medicines: a mixed-methods study. Patient 7(2), 177–185 (2014). doi:10.1007/s40271-013-0042-z

    Article  PubMed  Google Scholar 

  31. Himmel, W., Simmenroth-Nayda, A., Niebling, W., Ledig, T., Jansen, R.D., Kochen, M.M., Gleiter, C.H., Hummers-Pradier, E.: What do primary care patients think about generic drugs? Int. J. Clin. Pharmacol. Ther. 43(10), 472–479 (2005)

    Article  CAS  PubMed  Google Scholar 

  32. Quintal, C., Mendes, P.: Underuse of generic medicines in Portugal: an empirical study on the perceptions and attitudes of patients and pharmacists. Health Policy 104(1), 61–68 (2012). doi:10.1016/j.healthpol.2011.10.001

    Article  PubMed  Google Scholar 

  33. Mardetko, N., Kos, M.: Patients’ knowledge and attitude towards therapeutic reference pricing system in Slovenia. Int. J. Clin. Pharm. 38(5), 1301–1310 (2016). doi:10.1007/s11096-016-0370-x

    Article  PubMed  Google Scholar 

  34. Business News Daily: What is a BCG matrix? http://www.businessnewsdaily.com/5693-bcg-matrix.html (2016). Accessed 26 Nov 2016

  35. Stargardt, T.: The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. Eur. J. Health Econ. 11(3), 267–277 (2010). doi:10.1007/s10198-009-0172-3

    Article  PubMed  Google Scholar 

  36. Duel between the marketing authorisation holders and Health Insurance Institute of Slovenia. http://www.delo.si/zgodbe/ozadja/dvoboj-med-proizvajalci-zdravil-in-zzzs.html (2014). Accessed 20 Nov 2016

  37. Worries about that the mortality would be higher due to therapeutic reference pricing [in Slovenian]. http://www.zurnal24.si/skrbi-jih-da-bo-umrljivost-bolnikov-visja-terapevtske-skupine-zdravil-hipertenzija-clanek-241455 (2014). Accessed 26 Nov 2016

  38. Health Insurance Institute of Slovenia: The national health claims database. https://partner.zzzs.si/wps/portal/portali/aizv/zdravila_in_zivila_za_posebne_zdravstvene_namene/podatki_o_porabi_zdravil/!ut/p/z0/04_Sj9CPykssy0xPLMnMz0vMAfIjo8ziTQxdPd2N_Q08LSyCDQ0cjZzMzXz8XQ0sTAz0C7IdFQGdnpEx/ (2016). Accessed 8 Mar 2017

Download references

Author information

Authors and Affiliations

  1. Chair of Social Pharmacy, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000, Ljubljana, Slovenia

    Nika Marđetko & Mitja Kos

Authors
  1. Nika Marđetko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitja Kos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitja Kos.

Ethics declarations

Funding

None.

Conflict of interest

The authors declare that they have no conflicts of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 18 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marđetko, N., Kos, M. Introduction of therapeutic reference pricing in Slovenia and its economic consequences. Eur J Health Econ 19, 571–584 (2018). https://doi.org/10.1007/s10198-017-0903-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-017-0903-9

Keywords

JEL Classification

Search

Navigation